For The BMJ, Drew Altman discusses two fundamental policy decisions made by the Trump administration that set the U.S. on the controversial and highly criticized course it has taken on COVID-19.
- view as grid
- view as list
In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them.” But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of ‘wait and see’ Americans.”
Drew Altman discusses how systemic racism has led to striking levels of reluctance to get a COVID-19 vaccine among Black Americans, including those at highest risk, and the challenge it presents for ending the pandemic.
In this Axios column, Drew Altman says full FDA approval of COVID-19 vaccines can provide a big boost to vaccination efforts if treated as an opportunity for updated messaging from government officials at all levels and public health experts and new actions from employers.
In this Axios column, Drew Altman examines the lessons for COVID-19 as a political issue from Governor Gavin Newsom’s resounding win in California’s recall election.
In this Axios column, Drew Altman analyzes recent unemployment numbers for older workers and discusses how millions of uninsured older workers could lead to a greater push for incremental Medicare expansion proposals.
New analysis from Drew Altman in his latest Axios column on the impact of the coronavirus pandemic on national health spending.
Drew Altman’s Axios column draws on data from the new KFF COVID-19 Vaccine Monitor to assess where the country stands on vaccine hesitancy.
In this Axios column, Drew Altman looks at how the heroic performance of the nation’s doctors on the frontlines of coronavirus care and effective communication by many physician scientists on television, is shifting the public’s views, with twice as many Americans now saying doctors put people ahead of profits than they did in earlier KFF polling.
Drew Altman’s column in Axios: the U.S. now spends twice per capita what other wealthy countries do on health care. But while drug costs get all the time in public debate, it’s hospital and outpatient spending that mostly explains the difference. And that will be impossible to take on without real pain and political risk, he says.